CD47 and cancer: Herein, modulation of the TAM-dying cancer cell interface by targeting phagocytic pathways (e.g., CD47-SIRP1α, CAR-macrophages) is poised to be the next big breakthrough in immuno-oncology, contingent on successful results in ongoing clinical trials.